Ibiglustat is primarily used in the treatment of Gaucher disease, a genetic disorder characterized by the accumulation of glucocerebroside in cells and certain organs. It works by inhibiting the enzyme glucosylceramide synthase, which reduces the production of glucocerebroside, thereby alleviating the symptoms associated with the disease. This compound is particularly beneficial for patients who do not respond well to enzyme replacement therapy or substrate reduction therapy. Additionally, ibiglustat is being investigated for its potential therapeutic effects in other lysosomal storage disorders and neurodegenerative diseases, offering hope for broader applications in the future.